PD-156707: A selective endothelin-A receptor antagonist

Cardiovascular Drug Reviews

Volumn 16, Issue 2, 1998, Pages 89-104

  Uprichard, Andrew C G ^a   Metz, Alan L ^a   Hallak, Hussein ^a   Haleen, Stephen J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; ENDOTHELIN A RECEPTOR ANTAGONIST;

ARTERY OCCLUSION; ATHEROSCLEROSIS; DRUG METABOLISM; HEART FAILURE; HEART MUSCLE ISCHEMIA; HYPERTENSION; KIDNEY FAILURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; STROKE;

EID: 0031766019     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1998.tb00347.x     Document Type: Review

References (59)

1. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:730-732.
2. Baynash AG, Hosoda K, Giaid A, et al. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 1994;79:1277-1285.
3. Benigni A, Zoja C, Corna D, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993;44:440-444.
4. Cody WL, Doherty AM, He JX, et al. Design of a functional antagonist of endothelin. J Med Chem 1992;35:3301-3303.
5. B-receptor antagonist. Med Chem Res 1993;3:154-162.
6. B receptors in human vascular smooth muscle. J Cardiovasc Pharmacol (Suppl 8) 1993;22:S22-25.
7. Davenport AP, Maguire JJ. Endothelin receptors in human coronary artery-reply. Trends Pharmacol Sci 1994;5:136-137.
8. A sub-type. Br J Pharmacol 1995;114:1110-1116.
9. Detweiler DK. Spontaneous and induced arterial disease in the dog: Pathology and pathogenesis. Toxicol Pathol 1989;17:94-108.
10. Dogterom P, Zbinden G. Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: An overview. Crit Rev Toxicol 1992;22:203-241.
11. Doherty AM. Endothelin: A new challenge. J Med Chem 1992;35:1493-1508.
12. A) receptor-selective antagonists. J Med Chem 1995;38:1259-1263.
13. Doherty AM, Uprichard ACG. Discovery and development of an endothelin-A receptor selective antagonist PD 156707. In: Borchardt RT, et al., eds. Integration of pharmaceutical discovery and development: Case histories. New York: Plenum Press, 1998 (in press).
14. Ferro JF, Webb DJ. The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs 1996;51:12-27.
15. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New Engl J Med 1993;328:1732-1739.
16. Godfraind T. Endothelin receptors in human coronary artery. Trends Pharmacol Sci 1994;15:136.
17. Haleen SJ, Schroeder R, Walker D, et al. CI-1020 (PD 156707) prevents and reverses pulmonary hypertension in hypoxic rats. J Cardiovasc Pharmacol 1998 (in press).
18. Haleen SJ, Keiser JA, Gallagher KP, et al. Effects of chronic endothelin-A-receptor blockade on the progression of heart failure and survival in the cardiomyopathic hamster. Circulation 1998 (in press).
19. Harron JC, O'Rourke D, Gardiner T, Chakravarthy U, Uprichard ACG, Maxwell AP. Effect of an oral endothelin A receptor antagonist in a rat model of diabetic nephropathy. J Am Soc Nephrol 1997;8:637A.
20. Hartman HA. Spontaneous extramural coronary arteritis in dogs. Toxicol Pathol 1989;17:138-144.
21. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852-854.
22. Herman EH, Balazs T, Young R, Earl FL, Krop S, Ferrans V. Acute cardiomyopathy induced by the vasodilating antihypertensive agent Minoxidil. Toxicol Appl Pharmacol 1979;47:493-503.
23. Hosoda K, Nakao K, Arai H, et al. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991;287:23-26.
24. Hosoda K, Hammer RE, Richardson JA, et al. Targeted and natural (Piebald-Lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 1994;9:1267-1276.
25. Inoue A, Yanagisawa M, Kimura S, et al The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-2867.
26. A selectivity. Potency and solubility enhancing modifications. J Med Chem 1992;35:2139-2142.
27. Joseph EC, Jones HB, Kerns WD. Characterization of coronary arterial lesions in the dog following administration of SK&F 95654, a phophodiesterase-III inhibitor. Toxicol Pathol 1996;24:429-435.
28. A) antagonist, in acute hypoxic pulmonary hypertension. FASEB J 1997;11:A36.
29. Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994;368:703-710.
30. Masuda Y, Sugo T, Kikuchi T, et al. Receptor binding and antagonist properties of a novel endothelin receptor antagonist Tak-044 (cyclo[D-α-aspartyl-3-{(4-phenylpiperazin-1-yl)carbonyl}-L-alanyl-L-a- aspartyl-D-2-{2-thienyl}glycyl-L-leucyl-D-tryptophyl]disodium salt), in human endothelin A and endothelin B receptors. J Pharmacol Exp Ther 1996;279:675-685.
31. McClanahan TB, Mertz TE, Ignasiak DP, Junear PL, Gallagher KP. Effects of endothelin-receptor antagonism with PD 156707 on myocardial stunning in swine. J Cardiovasc Pharmacol 1996;28:679-686.
32. McConnell PI, Wang W, Gallagher K, Zucker IH. The effects of a specific endothelin-A (ETA) receptor antagonist on the development of chronic heart failure (HF) in the dog. FASEB J 1996;10:A430.
33. Mertz TE, McClanahan TB, Flynn MA, et al. Endothelin A receptor antagonism by PD 156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs. J Pharmacol Exp Ther 1996;278: 42-49.
34. Mesfin GM, Shawaryn GG, Higgins MJ. Cardiovascular alterations in dogs treated with hydralazine. Toxicol Pathol 1987;415:409-416.
35. Metz AL, Dominick MA, Suchanek G, Gough AW. Acute cardiovascular toxicity induced by an adenosine agonist-antihypertensive in beagles. Toxicol Pathol 1991;19:98-107.
36. Miller WL, Redfield MM, Burnett JC. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest 1989;83:317-320.
37. Mino N, Kobayashi M, Nakajima A, et al. Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure. Eur J Pharmacol 1992;221:77-83.
38. Omland T, Lie TJ, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as prognostic indicator on 1-year mortality after acute myocardial infarction. Circulation 1994;89:1573-1579.
39. Onley D, Yenari M, Sun GH, Kunis D, Steinberg GK. The endothelin-A antagonist PD 156707 is not neuroprotective in a model of experimental stroke. Soc Neurosci Abstr 1997;23:2440.
40. Patel TR, Galbraith SL, McAuley MA, Doherty AM, Graham DI, McCulloch J. Therapeutic potential of endothelin receptor antagonists in experimental stroke. J Cardiovasc Pharmacol 1995;26:S412-S415.
41. Patel TR. Therapeutic potential of endothelin receptor antagonists in cerebrovascular disease. CNS Drugs 1996;5:293-310.
42. Patel TR, Galbraith S, Graham DI, Hallak H, Doherty AM, McCulloch J. Endothelin receptor antagonist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia. J Cereb Blood Flow Metab 1996;16:950-958.
43. Peishoff CE, Lago MA, Ohlstein EH, Elliott JD. Endothelin receptor antagonists. Curr Pharmaceutical Design 1995;1:425-440.
44. Potter GS, Johnson RJ, Fink GD. Role of endothelin in hypertension of experimental chronic renal failure. Hypertension 1997;30:1578-1584.
45. A-receptor antagonist. J Pharmacol Exp Ther 1995a,273:1410-1417.
46. Reynolds EE, Hwang O, Flynn MA, et al. Pharmacological differences between rat and human endothelin B receptors. Biochem Biophys Res Commun 1995;209:506-512.
47. Ruben Z, Deslex P, Nash G, Redmond N, Poncet M, Dodd D. Spontaneous disseminated panarteritis in laboratory beagle dogs in a toxicity study: A possible genetic predilection. Toxicol Pathol 1989;17.145-152.
48. B endothelin receptor. Biochem Biophvs Res Commun 1991;178: 656-663
49. Sakurai T, Yanagisawa M, Takuwa Y, et al Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990;348:732-735.
50. Sandusky GE, Means JR, Yeager HK. Coronary artery toxicity in beagle dogs given Indolidan, a type III phosphodiesterase inhibitor. Fund Appl Toxicol 1993;21:228-235.
51. Schlaeppi B, Roncari G, Zahm P. Vascular toxicity in dogs associated with overdoses of a novel benzodiazepine receptor partial agonist. Arch Toxicol 1991;65:73-80.
52. Sobota JT. Review of cardiovascular findings in humans treated with minoxidil. Toxicol Pathol 1989;17: 193-202.
53. A-receptor antagonist. J Pharmacol Exp Ther 1993;64:1040-1046.
54. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits: Beneficial effects on left ventricular and myocyte function. Circulation 1997;95:1918-1929.
55. Takahashi K, Totsune K, Mouri T. Endothelin in chronic renal failure. Nephron 1994;66;373-379.
56. Takasago T, McCulloch J. Endothelin-A receptor blockade reduces infarction after focal cerebral ischemia in the rat. Cereb Blood Flow Metab 1997;17(1):661.
57. Tonnessen T, Nasee PA, Kirkedoen KA, Offstad J, Ilebekk A, Christenson G. Endothelin is released from the porcine coronary circulation after short-term ischemia. J Cardiovasc Pharmacol (Suppl 8) 1992;22: S313-S316.
58. Warner TD, Elliott JD, Ohlstein EH. California dreamin' 'about endothelin: Emerging new therapeutics. Trends Pharmacol Sci 1996;177-181.
59. Yanagisawa M, Hurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.